Hernandez-Boluda, JC, Pastor-Galan, I, Arellano-Rodrigo, E, Raya, JM, Perez-Encinas, M, Ayala, R, Ferrer-Marin, F, Velez, P, Mora, E, Fox, ML, Hernandez-Rivas, JM, Xicoy, B, Mata-Vazquez, MI, Garcia-Fortes, M, Perez-Lopez, R, Angona, A, Cuevas, B, Senin, A, Ramirez, MJ, Ramirez-Payer, A, Gomez-Casares, MT, Martinez-Valverde, C, Magro, E, Steegmann, JL, Duran, MA, Garcia-Hernandez, C, Gasior, M, de Villambrosia, SG, Alvarez-Larran, A, Pereira, A. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 199(4)DOI:10.1111/bjh.18440. PMID:36089912. IF:6.500(Q1/3D).

Triguero, A, Pedraza, A, Perez-Encinas, M, Mata-Vazquez, MI, Velez, P, Fox, L, Gomez-Calafat, M, Garcia-Delgado, R, Gasior, M, Ferrer-Marin, F, Garcia-Gutierrez, V, Angona, A, Gomez-Casares, MT, Cuevas, B, Martinez, C, Perez, R, Raya, JM, Guerrero, L, Murillo, I, Bellosillo, B, Hernandez-Boluda, JC, Sanz, C, Alvarez-Larran, A. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera. ANNALS OF HEMATOLOGY. 2022; 101(10)DOI:10.1007/s00277-022-04963-z. PMID:36042023. IF:3.500(Q2/5D).

Ramos-Muntada, M, Trincado, JL, Blanco, J, Bueno, C, Rodriguez-Cortez, VC, Bataller, A, Lopez-Millan, B, Schwab, C, Ortega, M, Velasco, P, Blanco, ML, Nomdedeu, J, Ramirez-Orellana, M, Minguela, A, Fuster, JL, Cuatrecasas, E, Camos, M, Ballerini, P, Escherich, G, Boer, J, DenBoer, M, Hernandez-Rivas, JM, Calasanz, MJ, Cazzaniga, G, Harrison, CJ, Menendez, P, Molina, O. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia. Molecular Oncology. 2022; 16(16)DOI:10.1002/1878-0261.13276. PMID:35726693. IF:6.600(Q1/3D).

Alvarez-Larran, A, Garrote, M, Ferrer-Marin, F, Perez-Encinas, M, Mata-Vazquez, MI, Bellosillo, B, Arellano-Rodrigo, E, Gomez, M, Garcia, R, Garcia-Gutierrez, V, Gasior, M, Cuevas, B, Angona, A, Gomez-Casares, MT, Martinez, CM, Magro, E, Ayala, R, del Orbe-Barreto, R, Perez-Lopez, R, Fox, ML, Raya, JM, Guerrero, L, Garcia-Hernandez, C, Caballero, G, Murillo, I, Xicoy, B, Ramirez, MJ, Carreno-Tarragona, G, Hernandez-Boluda, JC, Pereira, A. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea. CANCER. 2022; 128(13)DOI:10.1002/cncr.34195. PMID:35417564. IF:6.200(Q1/3D).